Cargando…
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926940/ https://www.ncbi.nlm.nih.gov/pubmed/20357770 http://dx.doi.org/10.1038/nsmb.1793 |
_version_ | 1782185738813571072 |
---|---|
author | Wojcik, John Hantschel, Oliver Grebien, Florian Kaupe, Ines Bennett, Keiryn L. Barkinge, John Jones, Richard B. Koide, Akiko Superti-Furga, Giulio Koide, Shohei |
author_facet | Wojcik, John Hantschel, Oliver Grebien, Florian Kaupe, Ines Bennett, Keiryn L. Barkinge, John Jones, Richard B. Koide, Akiko Superti-Furga, Giulio Koide, Shohei |
author_sort | Wojcik, John |
collection | PubMed |
description | Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibody-mimic or ‘monobody’, termed HA4, that bound to the Abl kinase SH2 domain with low nanomolar affinity. SH2 protein microarray analysis and mass spectrometry of intracellular HA4 interactors demonstrated HA4's exquisite specificity, and a crystal structure revealed how this specificity is achieved. HA4 disrupted intramolecular interactions of Abl involving the SH2 domain and potently activated the kinase in vitro. Within cells, HA4 inhibited processive phosphorylation activity of Abl and also STAT5 activation. This work provides a design guideline for highly specific and potent inhibitors of a protein interaction domain and demonstrates their utility in mechanistic and cellular investigations. |
format | Text |
id | pubmed-2926940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
record_format | MEDLINE/PubMed |
spelling | pubmed-29269402010-10-01 A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain Wojcik, John Hantschel, Oliver Grebien, Florian Kaupe, Ines Bennett, Keiryn L. Barkinge, John Jones, Richard B. Koide, Akiko Superti-Furga, Giulio Koide, Shohei Nat Struct Mol Biol Article Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibody-mimic or ‘monobody’, termed HA4, that bound to the Abl kinase SH2 domain with low nanomolar affinity. SH2 protein microarray analysis and mass spectrometry of intracellular HA4 interactors demonstrated HA4's exquisite specificity, and a crystal structure revealed how this specificity is achieved. HA4 disrupted intramolecular interactions of Abl involving the SH2 domain and potently activated the kinase in vitro. Within cells, HA4 inhibited processive phosphorylation activity of Abl and also STAT5 activation. This work provides a design guideline for highly specific and potent inhibitors of a protein interaction domain and demonstrates their utility in mechanistic and cellular investigations. 2010-03-28 2010-04 /pmc/articles/PMC2926940/ /pubmed/20357770 http://dx.doi.org/10.1038/nsmb.1793 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Wojcik, John Hantschel, Oliver Grebien, Florian Kaupe, Ines Bennett, Keiryn L. Barkinge, John Jones, Richard B. Koide, Akiko Superti-Furga, Giulio Koide, Shohei A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title | A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title_full | A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title_fullStr | A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title_full_unstemmed | A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title_short | A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain |
title_sort | potent and highly specific fn3 monobody inhibitor of the abl sh2 domain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926940/ https://www.ncbi.nlm.nih.gov/pubmed/20357770 http://dx.doi.org/10.1038/nsmb.1793 |
work_keys_str_mv | AT wojcikjohn apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT hantscheloliver apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT grebienflorian apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT kaupeines apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT bennettkeirynl apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT barkingejohn apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT jonesrichardb apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT koideakiko apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT supertifurgagiulio apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT koideshohei apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT wojcikjohn potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT hantscheloliver potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT grebienflorian potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT kaupeines potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT bennettkeirynl potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT barkingejohn potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT jonesrichardb potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT koideakiko potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT supertifurgagiulio potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain AT koideshohei potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain |